# A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

> **NCT06405633** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Wave Life Sciences Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency

## Interventions

- **DRUG:** WVE-006

## Key facts

- **NCT ID:** NCT06405633
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06405633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06405633, "A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06405633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*